Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Their primary mechanisms of action include: Enhancing glucose-dependent insulin secretion from pancreatic beta cells Suppressing glucagon release , which reduces hepatic glucose production Slowing gastric emptying , leading to prolonged satiety Acting on appetite centres in the brain to reduce food intake These combined effects result in improved glycaemic control, reduced HbA1c levels, and significant weight loss in many patients
Medications such as semaglutide (Wegovy) and liraglutide (Saxenda) are licensed for weight management, while other GLP-1 receptor agonists like dulaglutide (Trulicity) are licensed only for type 2 diabetes in the UK
Savyasachi Saxena | Dr
Alongside the long-acting injection, the company is developing oral obesity drugs and microneedle patches
US$ 25.87
US$ 22.02
US$ 29.79
US$ 29.97
US$ 24.51
